The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 19, 2022

Filed:

May. 08, 2018
Applicant:

The U.s.a., As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Joost J. Oppenheim, Bethesda, MD (US);

Dimiter S. Dimitrov, Pittsburgh, PA (US);

De Yang, Frederick, MD (US);

Xin Chen, Frederick, MD (US);

Zhongyu Zhu, Frederick, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 47/69 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 47/6415 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01);
Abstract

A human monoclonal antibody that specifically binds tumor necrosis factor receptor 2 (TNFR2), and a defucosylated form of the antibody, are described. The TNFR2-specific antibody was isolated from a human scFv phage display antibody library. The disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2CD4T regulatory cells in a dose- and time-dependent manner. Methods of using the TNFR2 antibodies, such as for tumor immunotherapy, are described.


Find Patent Forward Citations

Loading…